Bristol-myers Squibb Compnay

Qingjie Liu

Douglas G Batt

Scott Hunter Watterson

Saleem Ahmad

Joseph Anthony Tino

Qing Shi

John E Macor

George V Delucca

Anurag S Srivastava

Myra Beaudoin Bertrand

Soo Sung Ko

Charles Malcolm Langevine

Robert J Cherney

Satheesh Kesavan Nair

Khehyong Ngu

Andrew J Tebben

Lyndon A M Cornelius

Tarun Kumar Maishal

Michael A Galella

T G Murali Dhar

Chunjian Liu

David Marcoux

Lan-Ying Qin

Michael A Poss

Amit Kumar

Jingwu Duan

Stephen T Wrobleski

Michael G Yang

Steven H Spergel

David S Weinstein

John S Tokarski

Hai-Yun Xiao

James M Lin

Rajeev S Bhide

Scott Hunter

John L Gilmore

Kurt Zimmermann

Harold A Mastalerz

Zili Xiao

Ashok Vinayak Purandare

Ryan M Moslin

Shuqun Lin

Trevor C Sherwood

Hua Gong

Zheming Ruan

Weiwei Guo

Guifen Zhang

Walter Lewis Johnson

Yanlei Zhang

James Neels

George V De Lucca

Jianqing Li

Carolyn A Weigelt

Tg Murali Dhar

Lyndon AM Cornelius

Charles M Langevine

Disclosed are compounds of Formula (I): or a salt thereof, wherein: X is CRor N; R, R, R, R, and A are defined herein. Also disclosed are methods of using such compounds as inhibitors of Bruton's tyrosine kinase (Btk), and pharmaceutical compositions comprising such compounds. These compounds are useful in treating, preventing, or slowing the progression of diseases or disorders in a variety of therapeutic areas, such as autoimmune diseases and vascular disease.

Indole carboxamide compounds

Disclosed are compounds of Formula (I): or a salt thereof, wherein Q, R, R, R, R, R, R, R, R, R, R, R, R, R, and Rare defined herein. Also disclosed are methods of using such compounds as inhibitors of Bruton's tyrosine kinase (Btk), and pharmaceutical compositions comprising such compounds. These compounds are useful in treating, preventing, or slowing the progression of diseases or disorders in a variety of therapeutic areas, such as autoimmune diseases and vascular disease.

Carbazole derivatives

There are described ROR&#x3b3; modulators of the formula (I), or stereoisomers, tautomers, pharmaceutically acceptable salts, solvates, or prodrugs thereof, wherein all substituents are defined herein. Also provided are pharmaceutical compositions comprising the same. Such compounds and compositions are useful in methods for modulating ROR&#x3b3; Gamma activity in a cell and methods for treating a subject suffering from a disease or disorder in which the subject would therapeutically benefit from modulation of ROR&#x3b3; Gamma activity, for example, autoimmune and/or inflammatory disorders. 

Heterocyclic sulfones as ROR gamma modulators

Disclosed are compounds of Formula (I) wherein: the two dotted lines represent either two single or two double bonds; Q is: Ris F, Cl, &#x2014;CN, or &#x2014;CH; Ris Cl or &#x2014;CH; Ris &#x2014;C(CH)OH or &#x2014;CHCHOH; Ris H or &#x2014;CH; each Ris independently F, Cl, &#x2014;CH, and/or &#x2014;OCH; and n is zero, 1, or 2. Also disclosed are methods of using such compounds as inhibitors of Bruton's tyrosine kinase (Btk), and pharmaceutical compositions comprising such compounds. These compounds are useful in treating, preventing, or slowing the progression of diseases or disorders in a variety of therapeutic areas, such as autoimmune diseases and vascular disease.

Substituted tetrahydrocarbazole and carbazole carboxamide compounds

Disclosed are compounds of Formula (I): (I) or a salt thereof, wherein Q, R, R, R, R, R, R, R, R, R, R, R, R, R, and Rare defined herein. Also disclosed are methods of using such compounds as inhibitors of Bruton's tyrosine kinase (Btk), and pharmaceutical compositions comprising such compounds. These compounds are useful in treating, preventing, or slowing the progression of diseases or disorders in a variety of therapeutic areas, such as autoimmune diseases and vascular disease. 

Disclosed are compounds of Formula (I) or a salt thereof; wherein: X is N or CH; Qis: (i) Cl, Br, I, &#x2014;CN, &#x2014;CH, or &#x2014;CF; (ii) a 5-membered heteroaryl selected from pyrrolyl, pyrazolyl, imidazolyl, oxazolyl, thiazolyl, triazolyl, oxadiazolyl, and thiadiazolyl; (iii) a 6?membered heteroaryl selected from pyridinyl, pyridazinyl, and pyrimidinyl; or (iv) a bicyclic heteroaryl selected from indolyl, pyrrolopyridinyl, pyrazolopyridinyl and benzo[d]oxazolyl; wherein each of said 5-membered, 6-membered, and bicyclic heteroaryl is substituted with zero to 1 Rand zero to 1 R; and R, R, R, R, R, R, R, and Rare defined herein. Also disclosed are methods of using such compounds as modulators of PI3K, and pharmaceutical compositions comprising such compounds. These compounds are useful in treating, preventing, or slowing inflammatory and autoimmune diseases. 

Bicyclic heteroaryl amine compounds

Compounds having the following formula I: or a stereoisomer or pharmaceutically-acceptable salt thereof, where R, R, R, R, and Rare as defined herein, are useful in the modulation of IL-12, IL-23 and/or IFN&#x3b1;, by acting on Tyk-2 to cause signal transduction inhibition.

Amide-substituted heterocyclic compounds useful as modulators of IL-12, IL-23 and/or IFN alpha responses

There are described ROR&#x3b3; modulators of the formula (I), and formula (II) or stereoisomers, tautomers, pharmaceutically acceptable salts, solvates, or prodrugs thereof, wherein all substituents are defined herein. Also provided are pharmaceutical compositions comprising the same. Such compounds and compositions are useful in methods for modulating ROR&#x3b3; activity in a cell and methods for treating a subject suffering from a disease or disorder in which the subject would therapeutically benefit from modulation of ROR&#x3b3; activity, for example, autoimmune and/or inflammatory disorders.

Tricyclic sulfones as ROR&#x3b3; modulators

Disclosed are compounds of Formula (I); and salts thereof, wherein: Formula (II); Q is: Ris &#x2014;C(CH)2OH, &#x2014;NHC(=0)C(CH), &#x2014;N(CH3)2, or &#x2014;CHR; Ris CI or &#x2014;CH; Ris H, F, or &#x2014;CH; Ris H or &#x2014;CH; Ris H, F, CI, or &#x2014;OCH3 Ris H or F; and Rd is &#x2014;OH, &#x2014;OCH3, &#x2014;NHC(=0)CH3, or fORMULA (III), Also disclosed are methods of using such compounds as inhibitors of Bruton's tyrosine kinase (Btk), and pharmaceutical compositions comprising such compounds. These compounds are useful in treating, preventing, or slowing the progression of diseases or disorders in a variety of therapeutic areas, such as autoimmune diseases and vascular disease. 

Carbazole carboxamide compounds

Growing community of inventors

Newtown, PA, United States of America

Qingjie Liu